Iran, Australia Jointly Developing COVID Vaccine
TEHRAN (Tasnim) – Companies from Iran and Australia are jointly working on a coronavirus vaccine that is expected to become available in late September, an Iranian official said.
The official, who is a member of the board of directors of the Syndicate of Iranian Human Medicines Industries, said the coronavirus vaccine developed jointly by Iran and Australia is undergoing the third phase of clinical trials.
Haleh Hamedifar said the first phase of the tests have been carried out in Australia and the second and third phases began simultaneously on August 7.
She noted that the joint product, dubbed Spicogen, is expected to be an effective vaccine against the coronavirus, hoping that the first batch of the vaccine would become available by late September.
She also noted that the second and third phases of trial of the vaccine have been carried out by the Australian-based research company, which is not a mass-producer of vaccine, while the Iranian company CinnaGen will be producing that vaccine in mass amounts.
Iranian scientists and experts have succeeded in developing several vaccines against the coronavirus, despite the cruel sanctions imposed by the US.
Human injection of the first phase of clinical studies of the first coronavirus vaccine, made by Iranian researchers called COVIran Barekat, began on December 29, 2020.
Iran has already granted emergency use authorization to Russian-made Sputnik V vaccine, Covaxin made by India’s Bharat Biotech, Oxford/AstraZeneca developed by Russia’s R-Pharm Group, and the AstraZeneca-SKBio made in South Korea.
